[Form 4] Ocular Therapeutix, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Pravin Dugel, Executive Chairman, President and CEO of Ocular Therapeutix, Inc. (OCUL), reported the sale of 21,494 shares of the company's common stock on 08/25/2025 under a pre-established durable automatic sale instruction intended to satisfy tax withholding for restricted stock units that vested on 08/22/2025. The shares were sold at a weighted average price of $12.04, with transaction prices ranging from $11.89 to $12.18. After the sale, the reporting person beneficially owned 3,227,244 shares directly and 250,361 shares indirectly through the Pravin Dugel 2024 Irrevocable Trust. The filing was signed by an attorney-in-fact on behalf of Mr. Dugel on 08/27/2025.

Positive

• Transaction disclosed as non-discretionary under a durable automatic sale instruction (10b5-1 plan), indicating procedural compliance
• Detailed pricing range and weighted average ($11.89–$12.18; weighted avg $12.04) provided for the executed sales
• Substantial remaining ownership reported: 3,227,244 shares directly and 250,361 shares indirectly via trust

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Sale appears to be routine tax-related disposition under a pre-established plan; disclosure aligns with Section 16 reporting requirements.

The Form 4 shows a non-discretionary sell-to-cover transaction executed under a durable instruction adopted February 21, 2024, to satisfy tax withholding on vested restricted stock units. Use of an automatic plan and the clear explanation in the footnotes support transparency and compliance with insider trading rules. The reporting person retains substantial direct and indirect holdings, and the filing documents the weighted average sale price and price range for the executed trades.

Securities Analyst

TL;DR: Transaction is operationally routine; provides precise trade pricing and updated ownership totals for investor records.

The disclosure provides specific transactional detail: 21,494 shares sold at a weighted average of $12.04 with prices between $11.89 and $12.18. It updates beneficial ownership to 3,227,244 shares directly and 250,361 indirectly via a trust. This level of detail aids market transparency but does not, on its face, indicate a change in strategic ownership or control.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dugel Pravin

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		S(1)		21,494(1)	D	$12.04(2)	3,227,244	D
Common Stock								250,361	I	By Pravin Dugel 2024 Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2025. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.89 to $12.18, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Remarks:

Executive Chairman, President and CEO

	/s/ Todd Anderman, Attorney-in-Fact for Pravin Dugel	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What shares did Pravin Dugel sell according to the Form 4 for OCUL?

The Form 4 reports the sale of 21,494 shares of Ocular Therapeutix common stock on 08/25/2025.

Why were the shares sold by Pravin Dugel?

The shares were sold pursuant to a durable automatic sale instruction adopted February 21, 2024, effecting a sell-to-cover election to satisfy tax withholding for RSUs that vested on 08/22/2025.

At what price were the OCUL shares sold in the reported transaction?

The weighted average price was $12.04; sales occurred at prices ranging from $11.89 to $12.18.

How many OCUL shares does Pravin Dugel own after the transaction?

The filing reports 3,227,244 shares owned directly and 250,361 shares owned indirectly through the Pravin Dugel 2024 Irrevocable Trust.

What is Pravin Dugel's role at Ocular Therapeutix as stated in the filing?

The filing lists the reporting person as a Director and an Officer; remarks specify Executive Chairman, President and CEO.